TD Cowen analyst Steven Mah lowered the firm’s price target on 23andMe to $3 from $5 and keeps an Outperform rating on the shares. The firm noted they announced their highly anticipated Total Health and reiterated focus on recurring subscription revenue versus legacy testing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ME:
- 23andMe launches Total Health, a new health membership
- 23andMe reports updated safety, preliminary efficacy data from Phase 1/2a study
- 23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
- 23andMe launches Health Action Plan to provide personalized recommendations
- 23andMe enters collaboration extension with data licensing agreement with GSK